Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?

European Journal of Surgical Oncology

Volumn 40, Issue 11, 2014, Pages 1578-1585

  Buc, E ^a   Couvelard, A ^a   Kwiatkowski, F ^b   Dokmak, S ^a   Ruszniewski, P ^a   Hammel, P ^a   Belghiti, J ^a   Sauvanet, A ^a  

^a BEAUJON HOSPITAL   (France)

^b CENTRE JEAN PERRIN   (France)

Author keywords

Lymph node; Pancreatic cancer; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERINEURAL INVASION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL MORTALITY; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HISTORY; LYMPH NODE; LYMPH NODE DISSECTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; COHORT STUDIES; DISEASE-FREE SURVIVAL; HISTORY, ANCIENT; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84922480573     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.04.012     Document Type: Article

References (30)

1. Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 2007;67:2293-310.
2. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.
3. Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010;211:196-204.
4. Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11:350-6.
5. Pai RK, Beck AH, Mitchem J, Linehan DC, Chang DT, Norton JA. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to nodenegative disease. Am J Surg Pathol 2011;35:228-34.
6. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007;94:265-73.
7. Wind J, Lagarde SM, Ten Kate FJ, Ubbink DT, Bemelman WA, van Lanschot JJ. A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol 2007;33:401-8.
8. Wind J, ten Kate FJ, Kiewiet JJ, et al. The prognostic significance of extracapsular lymph node involvement in node positive patients with colonic cancer. Eur J Surg Oncol 2008;34:390-6.
9. Konstantinidis IT, Deshpande V, Zheng H, et al. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg 2010;14:261-7.
10. Varty PP, Yamamoto H, Farges O, Belghiti J, Sauvanet A. Early retropancreatic dissection during pancreaticoduodenectomy. Am J Surg 2005;189:488-91.
11. Pessaux P, Varma D, Arnaud JP. Pancreaticoduodenectomy: superior mesenteric artery first approach. J Gastrointest Surg 2006;10:607-11.
12. Kwiatkowski F, Girard M, Hacene K, Berlie J. [Sem: a suitable statistical software adaptated for research in oncology]. Bull Cancer 2000;87:715-21.
13. Ozaki H, Hiraoka T, Mizumoto R, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999;29:16-22.
14. Kawamata H, Yamashita K, Nakamura K, et al. Perineural invasion and preoperative serum CA19-9 as predictors of survival in biliary tract cancer. Anticancer Res 2013;33:583-94.
15. House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007;11:1549-55.
16. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549-58.
17. Massucco P, Ribero D, Sgotto E, Mellano A, Muratore A, Capussotti L. Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers. Ann Surg Oncol 2009;16:3323-32.
18. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165-74.
19. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10:1199-210. discussion 210-1.
20. Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas 2008;37:352-7.
21. Hellan M, Sun CL, Artinyan A, et al. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 2008;37:19-24.
22. Artinyan A, Hellan M, Mojica-Manosa P, et al. Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. Cancer 2008;112:34-42.
23. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-8.
24. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-40. discussion 40.
25. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.
26. Sahin TT, Fujii T, Kanda M, et al. Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. Pancreas 2011;40:1029-33.
27. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer 2001;84:864-73.
28. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabinebased combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
29. Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancerea Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228-36.
30. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-95.